Covishield and Blood Clots: Understanding Thrombocytopenia Thrombosis

The manufacturer of the Covishield vaccine has admitted in a London court that some people can experience side effects from the vaccine. This statement has caused concern in several countries.

The COVID-19 pandemic of 2020 claimed millions of lives worldwide, and it was a difficult time for everyone. Governments worked together to protect their citizens and implemented measures to control the spread of the virus.

Covaccine and Covishield Vaccination:

In response to the pandemic, people were urged to get vaccinated, and Covaccine and Covishield were developed to prevent COVID-19. As vaccination became mandatory, some people began to question the safety of these vaccines. When asked if the vaccine could be life-threatening, drug companies denied it.

However, a case was filed in a London court alleging that many people suffered health problems after receiving the vaccine. During the trial, AstraZeneca, in collaboration with Oxford University, which produced CoviShield, admitted that some people had died or experienced severe harm after receiving the vaccine.

The company stated that blood clots and Thrombosis with Thrombocytopenia Syndrome (TTS) were rare side effects of the vaccine. The company emphasized that not everyone who received the vaccine experienced these side effects, and they were very rare.

In 2023, the World Health Organization (WHO) issued a report stating that a new adverse event called Thrombosis with Thrombocytopenia Syndrome (TTS) had emerged in people who received COVID-19 non-replicant adenovirus vector-based vaccines.

What is Thrombocytopenia-Thrombosis Syndrome?

Thrombocytopenia-Thrombosis Syndrome (TTS), also known as vaccine-induced immune thrombotic thrombocytopenia (VITT), is a rare condition that can occur after vaccination with certain adenoviral vector COVID-19 vaccines, such as AstraZeneca's and Johnson & Johnson's vaccines. It is important to note that the risk of TTS is very low, and the benefits of these vaccines in preventing severe COVID-19 far outweigh the risks.

TTS is characterized by blood clots (thrombosis) forming in unusual places in the body, along with a low platelet count (thrombocytopenia). Platelets are cells in the blood that help it to clot. When there are not enough platelets, a person is at risk of excessive bleeding.